The Food and Drug Administration has approved Viberzi (eluxadoline) and Xifaxan (rifaximin) to treat irritable bowel syndrome with diarrhea (IBS-D) in adults, the agency announced May 27.
Viberzi is...
Despite birth rates among American teenagers continuing to decrease in recent years, not enough sexually active teens know of and use LARC, which the ... More »
The United States is currently experiencing an outbreak of shigellosis caused by a strain of the Shigella sonnei bacteria that is resistant to ciprofl... More »
Numerous states have achieved Healthy People 2020 goals for colorectal and cervical cancer incidence, and the proportion of persons with cancer who su... More »
SILVER SPRING, MD – A less-invasive alternative to liposuction and other cosmetic treatments for submental fat will likely become available in the U... More »
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to support proposed recommendations for use of t... More »
A vaginally inserted device that uses a balloon inflated by the patient to occlude the rectum has been cleared for marketing as a treatment for fecal ... More »
A vaginally inserted device that uses a balloon inflated by the patient to occlude the rectum has been cleared for marketing as a treatment for fecal ... More »
The Food and Drug Administration has approved the kinase inhibitor lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer, the agency... More »
A collagen dermal filler already on the market has been approved for improving the appearance of acne scars in people aged 21 years and older.
The f... More »